Advertisement

Screening for Diabetes and Prediabetes

  • Laura J. Gray
  • Andrew Willis
  • David Webb
  • Melanie J. Davies
  • Kamlesh Khunti
Reference work entry
Part of the Endocrinology book series (ENDOCR)

Abstract

Type 2 Diabetes and Prediabetes are serious conditions which can lead to early morbidity and mortality. The numbers of people with Type 2 Diabetes and Prediabetes are increasing and by 2040 it is estimated that there will be 642 million cases of diabetes alone worldwide, with many more people having Prediabetes. Type 2 diabetes can remain undiagnosed for many years and therefore screening can bring forward diagnosis, allowing treatment to be started earlier which may reduce diabetes related complications. Type 2 Diabetes is preventable in those with Prediabetes and therefore screening can be used to identify those with Prediabetes for inclusion in prevention programmes. In this chapter we consider the evidence for screening for both Type 2 Diabetes and Prediabetes, using case studies throughout to highlight issues.

Keywords

Type 2 Diabetes Mellitus Prediabetes Screening Prevention 

References

  1. ADA. 2. Classification and diagnosis of diabetes. Diabetes Care. 2016;39(Suppl 1):S13–22.Google Scholar
  2. AlGhamdi AST, Merdad K, Sonbul H, Bukhari SM, Elias WY. Dental clinics as potent sources for screening undiagnosed diabetes and prediabetes. Am J Med Sci. 2013;345(4):331–4.PubMedCrossRefGoogle Scholar
  3. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care. 2004;27:s5–s10.CrossRefGoogle Scholar
  4. American Diabetes Association. Summary of revisions for the 2010 clinical practice recommendations. Diabetes Care. 2010;33:S3.CrossRefGoogle Scholar
  5. Barber SR, Dhalwani NN, Davies MJ, Khunti K, Gray LJ.External national validation of the Leicester Self-Assessment score for Type 2 diabetes using data from the English Longitudinal Study of Ageing. Diabet Med. 2017 Nov;34(11):1575–1583.  https://doi.org/10.1111/dme.13433. Epub 2017 Aug 20.PubMedCrossRefGoogle Scholar
  6. Bland M. An introduction to medical statistics. Oxford: Oxford University Press; 2015.Google Scholar
  7. Bodicoat DH, Khunti K, Srinivasan BT, Mostafa S, Gray LJ, Davies MJ, Webb DR. Incident Type 2 diabetes and the effect of early regression to normoglycaemia in a population with impaired glucose regulation. Diabet Med. 2017 Mar;34(3):396–404.PubMedCrossRefGoogle Scholar
  8. Buijsse B, Simmons RK, Griffin SJ, Schulze MB. Risk assessment tools for identifying individuals at risk of developing type 2 diabetes. Epidemiol Rev. 2011;33(1):46–62.PubMedPubMedCentralCrossRefGoogle Scholar
  9. Chatterton H, Younger T, Fischer A, Khunti K, on behalf of the Programme Development Group. Risk identification and interventions to prevent type 2 diabetes in adults at high risk: summary of NICE guidance. BMJ. 2012;12(345):e4624.CrossRefGoogle Scholar
  10. Christensen J, Sandbæk A, Lauritzen T, Borch-Johnsen K. Population-based stepwise screening for unrecognised Type 2 diabetes is ineffective in general practice despite reliable algorithms. Diabetologia. 2004;47(9):1566–73.PubMedCrossRefGoogle Scholar
  11. Colchero MA, Popkin BM, Rivera JA, Ng SW. Beverage purchases from stores in Mexico under the excise tax on sugar sweetened beverages: observational study. BMJ. 2016;352:h6704.PubMedPubMedCentralCrossRefGoogle Scholar
  12. Collins GS, Mallett S, Omar O, Yu L. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. BMC Med. 2011;9:103.PubMedPubMedCentralCrossRefGoogle Scholar
  13. Committee NS. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. 2015. https://www.gov.uk/government/publications/evidence-review-criteria-national-screening-programmes/criteria-for-appraising-the-viability-effectiveness-and-appropriateness-of-a-screening-programme#the-condition. Retrieved 4 Aug 2016.
  14. Dalsgaard E-M, Christensen JO, Skriver MV, Borch-Johnsen K, Lauritzen T, Sandbaek A. Comparison of different stepwise screening strategies for type 2 diabetes: finding from Danish general practice, addition-DK. Prim Care Diabetes. 2010;4(4):223–9.PubMedCrossRefGoogle Scholar
  15. Dalton ARH, Bottle A, Okoro C, Majeed A, Millett C. Uptake of the NHS health checks programme in a deprived, culturally diverse setting: cross-sectional study. J Public Health. 2011.  https://doi.org/10.1093/pubmed/fdr034.PubMedCrossRefGoogle Scholar
  16. Davidson MB. Counterpoint: the oral glucose tolerance test is superfluous. Diabetes Care. 2002;25(10):1883–5.PubMedCrossRefGoogle Scholar
  17. Davidson MB, Peters AL, Schriger DL. An alternative approach to the diagnosis of diabetes with a review of the literature. Diabetes Care. 1995;18(7):1065–71.PubMedCrossRefGoogle Scholar
  18. Davies MJ, Gray LJ, Troughton J, Gray A, Tuomilehto J, Farooqi A, Khunti K, Yates T. A community based primary prevention programme for type 2 diabetes integrating identification and lifestyle intervention for prevention: the Let’s prevent diabetes cluster randomised controlled trial. Prev Med. 2016;84:48–56.PubMedCrossRefGoogle Scholar
  19. Department of Health. A vision for pharmacy in the new NHS. 2003. http://www.dh.gov.uk/prod_consum_dh/groups/dh_digitalassets/@dh/@en/documents/digitalasset/dh_4068356.pdf. Retrieved 10 Jan 2013.
  20. Diabetes Prevention Program Research Group. 10-year follow-up of diabetes incidence and weight loss in the diabetes prevention program outcomes study. Lancet. 2009;374(9702):1677–86.PubMedCentralCrossRefPubMedGoogle Scholar
  21. Dunkley AJ, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, Khunti K. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. Diabetes Care. 2014;37:922–33. Diabetes Care 37(6):1775–1776PubMedCrossRefGoogle Scholar
  22. Dunkley AJ, Tyrer F, Spong R, Gray LJ, Gillett M, Doherty Y, Martin-Stacey L, Patel N, Yates T, Bhaumik S, Chalk T, Chudasama Y, Thomas C, Sadler S, Cooper S, Gangadharan SK, Davies MJ, Khunti K. Screening for glucose intolerance and development of a lifestyle education programme for prevention of Type 2 diabetes in a population with intellectual disabilities. Programme Grants for Applied Research. Southampton (UK), In press; 2016.Google Scholar
  23. Eborall H, Stone M, Aujla N, Taub N, Davies M, Khunti K. Influences on the uptake of diabetes screening: a qualitative study in primary care. Br J Gen Pract. 2012;62(596):e204–11.PubMedPubMedCentralCrossRefGoogle Scholar
  24. Echouffo-Tcheugui JB, Dieffenbach SD, Kengne AP. Added value of novel circulating and genetic biomarkers in type 2 diabetes prediction: a systematic review. Diabetes Res Clin Pract. 2013;101(3):255–69.PubMedCrossRefGoogle Scholar
  25. Engberg S, Vistisen D, Lau C, Glümer C, Jørgensen T, Pedersen O, Borch-Johnsen K. Progression to impaired glucose regulation and diabetes in the population-based Inter99 study. Diabetes Care. 2009;32(4):606–11.PubMedCrossRefGoogle Scholar
  26. Erlinger TP, Brancati FL. Postchallenge hyperglycemia in a National Sample of U.S. adults with type 2 diabetes. Diabetes Care. 2001;24(10):1734–8.PubMedCrossRefGoogle Scholar
  27. Gallagher EJ, Bloomgarden ZT, Roith D. Review of hemoglobin A1c in the management of diabetes. J Diabetes. 2009;1:9–17.PubMedCrossRefGoogle Scholar
  28. Genco RJ, Schifferle RE, Dunford RG, Falkner KL, Hsu WC, Balukjian J. Screening for diabetes mellitus in dental practices: a field trial. J Am Dent Assoc. 2014;145(1):57–64.PubMedCrossRefGoogle Scholar
  29. George PM, Valabhji J, Dawood M, Henry JA. Screening for type 2 diabetes in the accident and emergency department. Diabet Med. 2005;22(12):1766–9.PubMedCrossRefGoogle Scholar
  30. Gerstein H, Santaguida P, Raina P, Morrison K, Balion C, Hunt D. Annual incidence and relative risk of diabetes in people with various categories of dysglycemia: a systematic overview and meta-analysis of prospective studies. Diabetes Res Clin Pract. 2007;78(3):305–12.PubMedCrossRefGoogle Scholar
  31. Gholap NN, Davies MJ, Mostafa SA, Khunti K. Diagnosing type 2 diabetes and identifying high-risk individuals using the new glycated haemoglobin (HbA1c) criteria. Br J Gen Pract. 2013;63(607):e165–7.PubMedPubMedCentralCrossRefGoogle Scholar
  32. Gillies CL, Abrams KR, Lambert PC, Cooper NJ, Sutton AJ, Hsu RT, Khunti K. Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis. BMJ. 2007;334(7588):299.PubMedPubMedCentralCrossRefGoogle Scholar
  33. Gillies CL, Lambert PC, Abrams KR, Sutton AJ, Cooper NJ, Hsu RT, Davies MJ, Khunti K. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. BMJ. 2008;336(7654):1180–5.PubMedPubMedCentralCrossRefGoogle Scholar
  34. Gomez-Peralta F, Abreu C, Andreu-Urioste L, Antolí AC, Rico-Fontsaré C, Martín-Fernández D, Resina-Rufes R, Pérez-García JJ, Negrete-Muñoz Á, Muñoz-Álvarez D, Umpierrez GE. Point-of-care capillary HbA1c measurement in the emergency department: a useful tool to detect unrecognized and uncontrolled diabetes. Int J Emerg Med. 2016;9(1):1–6.CrossRefGoogle Scholar
  35. Gong Q, Gregg EW, Wang J, An Y, Zhang P, Yang W, Li H, Jiang Y, Shuai Y, Zhang B, Zhang J, Gerzoff RB, Roglic G, Hu Y, Li G, Bennett PH. Long-term effects of a randomised trial of a 6-year lifestyle intervention in impaired glucose tolerance on diabetes-related microvascular complications: the China Da Qing diabetes prevention outcome study. Diabetologia. 2011;54(2):300–7.PubMedCrossRefGoogle Scholar
  36. Gray LJ, Taub N, Khunti K, Gardiner E, Hiles S, Webb DR, Srinivasan B, Davies MJ. The Leicester risk assessment score for detecting undiagnosed type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. Diabet Med. 2010a;27(8):887–95.PubMedCrossRefGoogle Scholar
  37. Gray LJ, Tringham J, Davies MJ, Webb DR, Jarvis J, Skinner TC, Farooqi A, Khunti K. Screening for type 2 diabetes in a multiethnic setting using known risk factors to identify those at high risk: a cross-sectional study. J Vasc Health Risk Manag. 2010b;6:837–42.CrossRefGoogle Scholar
  38. Gray LJ, Davies MJ, Hiles S, Taub NA, Webb DR, Srinivasan BT, K. K. Detection of impaired glucose regulation and/or type 2 diabetes mellitus, using primary care electronic data, in a multiethnic UK community setting. Diabetologia. 2012a;55(4):959–66.PubMedCrossRefGoogle Scholar
  39. Gray LJ, Khunti K, Edwardson C, Goldby S, Henson J, Morris DH, Sheppard D, Webb D, Williams S, Yates T, Davies MJ. Implementation of the automated Leicester practice risk score in two diabetes prevention trials provides a high yield of people with abnormal glucose tolerance. Diabetologia. 2012b;55(12):3238–44.PubMedCrossRefGoogle Scholar
  40. Gray LJ, Khunti K, Williams S, Goldby S, Troughton J, Yates T, Gray A, Davies MJ. Let's prevent diabetes: study protocol for a cluster randomised controlled trial of an educational intervention in a multi-ethnic UK population with screen detected impaired glucose regulation. Cardiovasc Diabetol. 2012c;11:56.PubMedPubMedCentralCrossRefGoogle Scholar
  41. Gray LJ, Yates T, Troughton J, Khunti K, Davies MJ. Engagement, retention, and progression to type 2 diabetes: a retrospective analysis of the cluster-randomized “Let’s Prevent Diabetes” trial. PLoS Med. 2016;13(7):e1002078.  https://doi.org/10.1371/journal.pmed.1002078.PubMedPubMedCentralCrossRefGoogle Scholar
  42. Griffin SJ, Borch-Johnsen K, Davies MJ, Khunti K, Rutten GE, Sandbæk A, Sharp SJ, Simmons RK, van den Donk M, Wareham NJ, Lauritzen T. Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial. Lancet. 2011;378(9786):156–67.PubMedPubMedCentralCrossRefGoogle Scholar
  43. Harris MI, Klein R, Welborn TA, Knuiman MW. Onset of NIDDM occurs at least 4-7 yr before clinical diagnosis. Diabetes Care. 1992;15(7):815–9.PubMedCrossRefGoogle Scholar
  44. Harris R, Donahue K, Rathore SS, Frame P, Woolf SH, Lohr KN. Screening adults for type 2 diabetes: a review of the evidence for the U.S. preventive services task force. Ann Intern Med. 2003;138:215–29.PubMedCrossRefGoogle Scholar
  45. Herman WH, Ma Y, Uwaifo G. Differences in A1C by race and ethnicity among patients with impaired glucose tolerance in the Diabetes Prevention Program. Diabetes Care. 2007;30:2453–7.PubMedPubMedCentralCrossRefGoogle Scholar
  46. Herman WH, Ye W, Griffin SJ, Simmons RK, Davies MJ, Khunti K, Rutten GEHM, Sandbaek A, Lauritzen T, Borch-Johnsen K, Brown MB, Wareham NJ. Early detection and treatment of type 2 diabetes reduce cardiovascular morbidity and mortality: a simulation of the results of the Anglo-Danish-Dutch study of intensive treatment in people with screen-detected diabetes in primary care (ADDITION-Europe). Diabetes Care. 2015;38(8):1449–55.PubMedPubMedCentralCrossRefGoogle Scholar
  47. Hex N, Bartlett C, Wright D, Taylor M, Varley D. Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med. 2012;29(7):855–62.PubMedCrossRefGoogle Scholar
  48. Hng T-M, Hor A, Ravi S, Feng X, Lin J, Astell-Burt T, Chipps D, McLean M, Maberly G. Diabetes case finding in the emergency department, using HbA1c: an opportunity to improve diabetes detection, prevention, and care. BMJ Open Diabetes Res Care. 2016;4(1).CrossRefGoogle Scholar
  49. International Diabetes Federation. IDF diabetes atlas. 7th ed. International Diabetes Federation, Brussels, Belgium. 2015.Google Scholar
  50. Khunti K, Taub N, Gillies C, Abrams K, Hiles S, Webb D, Srinivasan B, Davies MJ. A comparison of screening strategies for impaired glucose tolerance and type 2 diabetes mellitus in a UK community setting: a cost per case analysis. Diabetes Res Clin Pract. 2012;97(3):505–13.PubMedCrossRefGoogle Scholar
  51. Khunti K, Mani H, Achana F, Cooper N, Gray LJ, Davies MJ. Systematic review and meta-analysis of response rates and diagnostic yield of screening for type 2 diabetes and those at high risk of diabetes. PLoS ONE. 2015;10(9):e0135702.  https://doi.org/10.1371/journal.pone.0135702.PubMedPubMedCentralCrossRefGoogle Scholar
  52. Khunti K, Gillies CL, Dallosso H, Brady EM, Gray LJ, Kilgallen G, Willis A, Zafar A, Davies MJ. Assessment of response rates and yields for two opportunistic tools for early detection of non-diabetic hyperglycaemia and diabetes (ATTEND). A randomised controlled trial and cost-effectiveness analysis. Diabetes Res Clin Pract. 2016;118:12–20.PubMedCrossRefGoogle Scholar
  53. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med. 2002;346(6):393–403.CrossRefPubMedPubMedCentralGoogle Scholar
  54. Kosaka K, Noda M, Kuzuya T. Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males. Diabetes Res Clin Pract. 2005;67(2):152–62.PubMedCrossRefGoogle Scholar
  55. Lalkhen AG, McCluskey A. Clinical tests: sensitivity and specificity. Contin Educ Anaesth Crit Care Pain. 2008;8(6):221–3.CrossRefGoogle Scholar
  56. Lalla E, Kunzel C, Burkett S, Cheng B, Lamster IB. Identification of unrecognized diabetes and pre-diabetes in a dental setting. J Dent Res. 2011;90(7):855–60.PubMedCrossRefGoogle Scholar
  57. Leal J, Ahrabian D, Gray AM. Cost effectiveness of a pragmatic structured education intervention for type 2 diabetes: economic evaluation of data from the Let’s Prevent trial. BMJ Open. 2015;7:e013592.  https://doi.org/10.1136/bmjopen-2016-013592.PubMedPubMedCentralCrossRefGoogle Scholar
  58. Lenters-Westra E, Slingerland RJ. Six of eight hemoglobin A1c point-of-care instruments do not meet the general accepted analytical performance criteria. Clin Chem. 2010;56(1):44–52.PubMedCrossRefGoogle Scholar
  59. Li G, Zhang P, Wang J, Gregg EW, Yang W, Gong Q, e. al. The long-term effect of lifestyle interventions to prevent diabetes in the China Da Qing diabetes prevention study: a 20-year follow-up study. Lancet. 2008;371(9626):1783–9.PubMedCrossRefGoogle Scholar
  60. Li S, Williams PL, Douglass CW. Development of a clinical guideline to predict undiagnosed diabetes in dental patients. J Am Dent Assoc. 2011;142(1):28–37.PubMedCrossRefGoogle Scholar
  61. Li G, Zhang P, Wang J, An Y, Gong Q, Gregg EW, Yang W, Zhang B, Shuai Y, Hong J, Engelgau MM, Li H, Roglic G, Hu Y, Bennett PH. Cardiovascular mortality, all-cause mortality, and diabetes incidence after lifestyle intervention for people with impaired glucose tolerance in the Da Qing diabetes prevention study: a 23-year follow-up study. Lancet Diabetes Endocrinol. 2014;2(6):474–80.PubMedCrossRefGoogle Scholar
  62. Lindström J, Tuomilehto J. The diabetes risk score. Diabetes Care. 2003;26(3):725–31.PubMedCrossRefGoogle Scholar
  63. Lindström J, Ilanne-Parikka P, Peltonen M, Aunola S, Eriksson J, Hemiö K, Hämäläinen H, Härkönen P, Keinänen-Kiukaanniemi S, Laakso M, Louheranta A, Mannelin M, Paturi M, Sundvall J, Valle T, Uusitupa M, Tuomilehto J, Finnish Diabetes Prevention Study Group. Sustained reduction in the incidence of type 2 diabetes by lifestyle intervention: follow-up of the Finnish diabetes prevention study. Lancet. 2006;368(9548):1673–9.PubMedCrossRefGoogle Scholar
  64. Meigs JB, Muller DC, Nathan DM, Blake DR, Andres R. The natural history of progression from normal glucose tolerance to type 2 diabetes in the Baltimore longitudinal study of aging. Diabetes. 2003;52(6):1475–84.PubMedCrossRefGoogle Scholar
  65. Morris DH, Khunti K, Achana F, Srinivasan B, Gray LJ, Davies MJ, Webb D. Progression rates from HbA1c 6.0–6.4% and other prediabetes definitions to type 2 diabetes: a meta-analysis. Diabetologia. 2013;56(7):1489–93.PubMedCrossRefGoogle Scholar
  66. Mostafa SA, Davies MJ, Webb D, Gray LJ, Srinivasan BT, Jarvis J, Khunti K. The potential impact of using glycated haemoglobin, HbA1c, as the preferred diagnostic tool for type 2 diabetes mellitus. Diabet Med. 2010a;72:762–9.CrossRefGoogle Scholar
  67. Mostafa SA, Khunti K, Srinivasan BT, Webb D, Gray LJ, Davies MJ. The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. Diabetes Res Clin Pract. 2010b;90(1):100–8.PubMedCrossRefGoogle Scholar
  68. Mostafa SA, Davies MJ, Webb DR, Srinivasan BT, Gray LJ, Khunti K. Independent effect of ethnicity on glycemia in south Asians and white Europeans. Diabetes Care. 2012;35(8):1746–8.PubMedPubMedCentralCrossRefGoogle Scholar
  69. Mozaffarian D, Kamineni A, Carnethon M, Djoussé L, Mukamal KJ, Siscovick D. Lifestyle risk factors and new-onset diabetes mellitus in older adults: the cardiovascular health study. Arch Intern Med. 2009;169(8):798–807.PubMedPubMedCentralCrossRefGoogle Scholar
  70. National Institute for Health and Clinical Excellence. Public health Guidence 38, preventing type 2 diabetes: risk identification and interventions for individuals at high risk. London: National Institute for Health and Clinical Excellence; 2012.Google Scholar
  71. National Institute of Health and Clinical Excellence. Preventing type 2 diabetes: risk identification and interventions for individuals at high risk. London: NICE; 2012.Google Scholar
  72. National Screening Committee. Criteria for appraising the viability, effectiveness and appropriateness of a screening programme. UK. http://www.screening.nhs.uk/criteria. 2003. Retrieved 1 June 2014.
  73. National Screening Committee. https://www.gov.uk/guidance/nhs-population-screening-explained. 2016. Retrieved 21 Mar 2016.
  74. Noble D, Mathur R, Dent T, Meads C, Greenhalgh T. Risk models and scores for type 2 diabetes: systematic review. BMJ. 2011;343:d7163.PubMedPubMedCentralCrossRefGoogle Scholar
  75. Paddison CAM, Eborall HC, Sutton S, French DP, Vasconcelos J, Prevost AT, Kinmonth A-L, Griffin SJ. Are people with negative diabetes screening tests falsely reassured? Parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ. 2009;339:b4535.PubMedPubMedCentralCrossRefGoogle Scholar
  76. Pan XR, Li GW, Hu YH, Wang JX, Yang WY, An ZX, Hu ZX. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and diabetes study. Diabetes Care. 1997;20(4):537–44.CrossRefGoogle Scholar
  77. Patel N, Willis A, Stone M, Barber S, Gray L, Davies M, Khunti K. Developing a conceptually equivalent type 2 diabetes risk score for Indian Gujaratis in the UK. J Diabetes Res. 2016;2016:9.Google Scholar
  78. Paul SK, Klein K, Thorsted BL, Wolden ML, Khunti K. Delay in treatment intensification increases the risks of cardiovascular events in patients with type 2 diabetes. Cardiovasc Diabetol. 2015;14(1):1.CrossRefGoogle Scholar
  79. Phung OJ, Sood NA, Sill BE, Coleman CI. Oral anti-diabetic drugs for the prevention of type 2 diabetes. Diabet Med. 2011;28(8):948–64.PubMedCrossRefGoogle Scholar
  80. Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ. Effect of screening for type 2 diabetes on population-level self-rated health outcomes and measures of cardiovascular risk: 13-year follow-up of the Ely cohort. Diabet Med. 2012a;29(7):886–92.PubMedPubMedCentralCrossRefGoogle Scholar
  81. Rahman M, Simmons RK, Hennings SH, Wareham NJ, Griffin SJ. How much does screening bring forward the diagnosis of type 2 diabetes and reduce complications? Twelve year follow-up of the Ely cohort. Diabetologia. 2012b;55:1651–9.PubMedCrossRefGoogle Scholar
  82. Ramachandran A, Snehalatha C, Mary S, Mukesh B, Bhaskar AD, Vijay V, Indian Diabetes Prevention Programme (IDPP). The Indian diabetes prevention programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). Diabetologia. 2006;49(2):289–97.PubMedCrossRefGoogle Scholar
  83. Rathmann W, Martin S, Haastert B, Icks A, Holle R, Lowel H, Giani G, for the Kora Study Group. Performance of screening questionnaires and risk scores for undiagnosed diabetes: the KORA survey 2000. Arch Intern Med. 2005;165(4):436–41.PubMedCrossRefGoogle Scholar
  84. Rathmann W, Kowall B, Tamayo T, Giani G, Holle R, Thorand B, Heier M, Huth C, Meisinger C. Hemoglobin A1c and glucose criteria identify different subjects as having type 2 diabetes in middle-aged and older populations: the KORA S4/F4 study. Ann Med. 2012;44(2):170–7.PubMedCrossRefGoogle Scholar
  85. Roper NA, Bilous RW, Kelly WF, Unwin NC, Connolly VM. Excess mortality in a population with diabetes and the impact of material deprivation: longitudinal, population based study. BMJ. 2001;322(7299):1389–93.PubMedPubMedCentralCrossRefGoogle Scholar
  86. Saaristo T, Peltonen M, Lindstrom J, Saarikoski L, Sundvall J, Eriksson JG, Tuomilehto J. Cross-sectional evaluation of the Finnish diabetes risk score: a tool to identify undetected type 2 diabetes, abnormal glucose tolerance and metabolic syndrome. Diab Vasc Dis Res. 2005;2(2):67–72.PubMedCrossRefGoogle Scholar
  87. Sandbaek A, Griffin SJ, Rutten G, Davies M, Stolk R, Khunti K, Borch-Johnsen K, Wareham NJ, T L. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia. 2008;51(7):1127–34.PubMedPubMedCentralCrossRefGoogle Scholar
  88. Sandbæk A, Griffin SJ, Sharp SJ, Simmons RK, Borch-Johnsen K, Rutten GEHM, van den Donk M, Wareham NJ, Lauritzen T, Davies MJ, Khunti K. Effect of early multifactorial therapy compared with routine care on microvascular outcomes at 5 years in people with screen-detected diabetes: a randomized controlled trial. The ADDITION-Europe study. Diabetes Care. 2014;37(7):2015–23.PubMedCrossRefGoogle Scholar
  89. Schaufler TM, Wolff M. Cost effectiveness of preventive screening programmes for type 2 diabetes mellitus in Germany. Appl Health Econ Health Policy. 2010;8(3):191–202.PubMedCrossRefGoogle Scholar
  90. Schwarz PE, Li J, Reimann M, Schutte AE, Bergmann A, Hanefeld M, Bornstein SR, Schulze J, Tuomilehto J, Lindström J. The Finnish diabetes risk score is associated with insulin resistance and progression towards type 2 diabetes. J Clin Endocrinol Metab. 2009;94(3):920–6.PubMedCrossRefGoogle Scholar
  91. Selph S, Dana T, Blazina I, Bougatsos C, Patel H, Chou R. Screening for type 2 diabetes mellitus: a systematic review for the U.S. preventive services task ForceScreening for type 2 diabetes mellitus. Ann Intern Med. 2015;162(11):765–76.PubMedCrossRefGoogle Scholar
  92. Simmons R, Echouffo-Tcheugui J, Griffin S. Screening for type 2 diabetes: an update of the evidence. Diabetes Obes Metab. 2010;12(10):838–44.PubMedCrossRefGoogle Scholar
  93. Simmons RK, Rahman M, Jakes RW, Yuyun MF, Niggebrugge AR, Hennings SH, Williams DRR, Wareham NJ, Griffin SJ. Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort. Diabetologia. 2011;54(2):312–9.PubMedCrossRefGoogle Scholar
  94. Stokes A, Mehta NK. Mortality and excess risk in US adults with pre-diabetes and diabetes: a comparison of two nationally representative cohorts, 1988–2006. Popul Health Metrics. 2013;11(1):1–7.CrossRefGoogle Scholar
  95. Strauss SM, Russell S, Wheeler A, Norman R, Borrell LN, Rindskopf D. The dental office visit as a potential opportunity for diabetes screening: an analysis using NHANES 2003-2004 data. J Public Health Dent. 2010;70(2):156–62.PubMedGoogle Scholar
  96. Tao L, Wilson ECF, Wareham NJ, Sandbæk A, Rutten GEHM, Lauritzen T, Khunti K, Davies MJ, Borch-Johnsen K, Griffin SJ, Simmons RK. Cost-effectiveness of intensive multifactorial treatment compared with routine care for individuals with screen-detected type 2 diabetes: analysis of the ADDITION-UK cluster-randomized controlled trial. Diabet Med. 2015;32(7):907–19.PubMedPubMedCentralCrossRefGoogle Scholar
  97. The Diabetes Prevention Program Research Group. Costs associated with the primary prevention of type 2 diabetes mellitus in the diabetes prevention program. Diabetes Care. 2003;26(1):36–47.PubMedCentralCrossRefPubMedGoogle Scholar
  98. The International Expert Committee. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. Diabetes Care. 2009;32:1327–34.PubMedCentralCrossRefPubMedGoogle Scholar
  99. Toscano CM, Duncan BB, Mengue SS, Polanczyk CA, Nucci LB, e Forti AC, Fonseca CD, Schmidt MI. Initial impact and cost of a nationwide population screening campaign for diabetes in Brazil: a follow up study. BMC Health Serv Res. 2008;8(1):1.CrossRefGoogle Scholar
  100. Toscano CM, Zhuo X, Imai K, Duncan BB, Polanczyk CA, Zhang P, Engelgau M, Schmidt MI. Cost-effectiveness of a national population-based screening program for type 2 diabetes: the Brazil experience. Diabetol Metab Syndr. 2015;7(1):1–11.CrossRefGoogle Scholar
  101. Troughton J, Chatterjee S, Hill SE, Daly H, Stacey LM, Stone MA, Patel N, Khunti K, Yates T, Gray LJ. Development of a lifestyle intervention using the MRC framework for diabetes prevention in people with impaired glucose regulation. J Public Health. 2016 Sep;38(3):493–501.PubMedCrossRefGoogle Scholar
  102. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, Keinanen-Kiukaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Aunola S, Cepaitis Z, Moltchanov V, Hakumaki M, Mannelin M, Martikkala V, Sundvall J, Uusitupa M, the Finnish Diabetes Prevention Study Group. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med. 2001;344(18):1343–50.PubMedCrossRefGoogle Scholar
  103. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352(9131):837–53.CrossRefGoogle Scholar
  104. Vernillo AT. Diabetes mellitus: relevance to dental treatment. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2001;91(3):263–70.PubMedCrossRefGoogle Scholar
  105. Vistisen D, Lee CM, Colagiuri S, Borch-Johnsen K, Glümer C. A globally applicable screening model for detecting individuals with undiagnosed diabetes. Diabetes Res Clin Pract. 2012;95(3):432–8.PubMedCrossRefGoogle Scholar
  106. Waugh N, Scotland G, McNamee P, Gillett M, Brennan A, Goyder E, Williams R, John A. Screening for type 2 diabetes: literature review and economic modelling. Health Technol Assess. 2007;11(17):1–125.PubMedCrossRefGoogle Scholar
  107. Waugh N, Shyangdan D, Taylor-Phillips S, Suri G, Hall B. Screening for type 2 diabetes: a short report for the National Screening Committee. 2013.Google Scholar
  108. Webb DR, Gray LJ, Khunti K, Srinivasan B, Taub N, Campbell S, Barnett J, Farooqi A, Echouffo-Tcheugui J, Griffin S, Wareham N, Davies M. Screening for diabetes using an oral glucose tolerance test within a western multi-ethnic population identifies modifiable cardiovascular risk: the ADDITION-Leicester study. Diabetologia. 2011;54(9):2237–46.PubMedCrossRefGoogle Scholar
  109. White M. Population approaches to prevention of type 2 diabetes. PLoS Med. 2016;13(7):e1002080.PubMedPubMedCentralCrossRefGoogle Scholar
  110. Williams DRR, Wareham NJ, Brown DC, Byrne CD, Clark PMS, Cox BD, Cox LJ, Day NE, Hales CN, Palmer CR, Shackleton JR, Wang TWM. Undiagnosed glucose intolerance in the community: the Isle of Ely diabetes project. Diabet Med. 1995;12(1):30–5.PubMedCrossRefGoogle Scholar
  111. Willis AW. The effectiveness of screening for type 2 diabetes within a community pharmacy setting. PhD, University of Leicester. 2015.Google Scholar
  112. Willis A, Roshan M, Patel N, Gray L, Yates T, Davies M, Khunti K. A community faith centre based screening and educational intervention to reduce the risk of type 2 diabetes: a feasibility study. Diabetes Res Clin Pract. 2016;120:73–80.PubMedCrossRefGoogle Scholar
  113. Wilson JMG, Jungner G. Principles and practice of screening for disease, Public health paper, vol. 34. Geneve: World Health Organization; 1968.Google Scholar
  114. Witte DR, Shipley MJ, Marmot MG, Brunner EJ. Performance of existing risk scores in screening for undiagnosed diabetes: an external validation study. Diabet Med. 2010;27(1):46.PubMedCrossRefGoogle Scholar
  115. World Health Organisation. Definition, diagnosis, and classification of diabetes mellitus and its complications. Report of a WHO consultation. Part 1: diagnosis and classification of diabetes mellitus. Geneva: World Health Organisation; 1999.Google Scholar
  116. World Health Organisation. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. Geneva: World Health Organisation; 2011.Google Scholar
  117. World Health Organization. Screening for type 2 diabetes. Report of a World Health Organization and International Diabetes Federation meeting. 2003.Google Scholar
  118. Zhuo X, Zhang P, Gregg EW, Barker L, Hoerger TJ, Pearson-Clarke T, Albright A. A nationwide community-based lifestyle program could delay or prevent type 2 diabetes cases and save $5.7 billion in 25 years. Health Aff. 2012;31(1):50–60.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2018

Authors and Affiliations

  • Laura J. Gray
    • 1
  • Andrew Willis
    • 2
  • David Webb
    • 2
  • Melanie J. Davies
    • 2
  • Kamlesh Khunti
    • 2
  1. 1.Department of Health SciencesUniversity of LeicesterLeicesterUK
  2. 2.Diabetes Research CentreUniversity of LeicesterLeicesterUK

Personalised recommendations